In a report released today, George Zavoico from B.Riley FBR maintained a Buy rating on Novavax (NASDAQ: NVAX), with a price target of $10. The company’s shares opened today at $1.68.
Zavoico noted:
“a premier peer-reviewed medical journal, published positive results of a randomized, observer-blinded Phase I/II clinical trial showing that Nanoflu, Novavax’s trivalent Matrix-M adjuvanted nanoparticle seasonal influenza vaccine candidate, generates a more robust immune response than the current market-leading, egg-based, high- dose seasonal influenza vaccine, called “Fluzone HD.” Antibody titers generated against five A(H3N2) virus strains and a single A(H1N1) and B strain by two doses of Nanoflu and Fluzone HD were compared 21 days after vaccination. Antibody titers generated against the A(H3N2) and A(H1N1) strains were up to 64% higher with Nanoflu than with Fluzone HD. Antibody titers against the B strain were equivalent.”
According to TipRanks.com, Zavoico is a 4-star analyst with an average return of 8.6% and a 45.2% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Cellular Biomedicine Group, Catalyst Biosciences Inc, and Actinium Pharmaceuticals.
Novavax has an analyst consensus of Hold, with a price target consensus of $4.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.75 and a one-year low of $0.91. Currently, Novavax has an average volume of 5.73M.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVAX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza, and Ebola virus.
Read More on NVAX:
